-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune secretory immunoglobulin A (IgA) antibodies are anti-human and animal models of intestinal infection in one of the main defense mechanism
.
IgA provides protection by binding to microbial antigens, toxins and food proteins, and inhibits the adhesion and penetration of the intestinal epithelium
.
Immune secretory immunoglobulin A (IgA) antibodies are anti-human and animal models of intestinal infection in one of the main defense mechanism
The use of probiotics is rapidly increasing, despite the questionable evidence of effectiveness, especially when it is associated with acute gastroenteritis (AGE) in children
In 2017 , Stephen B Freedman's team completed the outpatient gastroenteritis treatment probiotic program (PROGUT) clinical trial, which randomly selected older children to receive a Lactobacillus rhamnosus/Lactobacillus helveticus probiotic mixture or the same placebo.
The team recently published a research article in The American Journal of Clinical Nutrition to determine whether the fecal secretory immunoglobulin A (sIgA) concentration of children taking Lactobacillus rhamnosus/Lactobacillus helveticus probiotics varies with age compared with placebo Increase and increase .
The study uses a multi-center, randomized, double-blind, placebo-controlled auxiliary study, with children receiving 5-day probiotics or placebo treatment as the study subjects
.
The study uses a multi-center, randomized, double-blind, placebo-controlled auxiliary study, with children receiving 5-day probiotics or placebo treatment as the study subjects
Of the 886 PROGUT participants (15.
0%), a total of 133 (n=66 probiotics, 67 placebos) provided all 3 specimens
.
Of the 886 PROGUT participants (15.
There was no difference in fecal median sIgA concentration between the probiotic group and the placebo group at any study time point: median IQR on day 0: 1999 (768, 4071) and 2198 (702, 5278) (P=0.
Fecal sIgA concentrations in the probiotic (A) (n = 66) and placebo (B) (n = 67) treatment groups at baseline and 5 and 28 days after randomization treatment
.
Fecal sIgA concentrations in the probiotic (A) (n = 66) and placebo (B) (n = 67) treatment groups at baseline and 5 and 28 days after randomization treatment
Fecal sIgA concentrations of norovirus (A) and rotavirus (B) infected children at baseline and 5 and 28 days after randomized treatment
.
.
Although the sIgA in the stool of the two groups decreased from day 5 to day 28 (P<0.
001), the median change in sIgA concentration between the probiotic group and the placebo group was compared from day 0 to day 28.
The 5-day median (IQR) [500(-1135,2362) and 362(-1122,4256); P=0.
77, Cohen d=0.
075] and the 5th to the 28th day [-1035(-3130,499) ) And -1260 (-4437, 843); P=0.
70, Cohen d=0.
067] there is no difference
.
001), the median change in sIgA concentration between the probiotic group and the placebo group was compared from day 0 to day 28.
The 5-day median (IQR) [500(-1135,2362) and 362(-1122,4256); P=0.
77, Cohen d=0.
075] and the 5th to the 28th day [-1035(-3130,499) ) And -1260 (-4437, 843); P=0.
70, Cohen d=0.
067] there is no difference
.
This study quantified the effect of rhamnose/Swiss grass administration on sIgA concentration in feces of preschool children
.
Neither the rhamnose/Swiss grass group nor the placebo treatment group had a significant increase in sIgA concentration in stool within 5 days after the ED visit
.
After repeated measures and test sites were controlled, treatment had no effect on stool sIgA concentration
.
Although the stool sIgA concentration decreased significantly between the 5th day and the 28th day, this has nothing to do with the treatment allocation
.
In addition, it was found that there was no relationship between the severity of the disease and the concentration of sIgA in the stool
.
.
Neither the rhamnose/Swiss grass group nor the placebo treatment group had a significant increase in sIgA concentration in stool within 5 days after the ED visit
.
After repeated measures and test sites were controlled, treatment had no effect on stool sIgA concentration
.
Although the stool sIgA concentration decreased significantly between the 5th day and the 28th day, this has nothing to do with the treatment allocation
.
In addition, it was found that there was no relationship between the severity of the disease and the concentration of sIgA in the stool
.
In conclusion, in children with acute gastroenteritis in the emergency department, the rhamnose/swiss grass treatment did not increase the fecal sIgA concentration compared with placebo
.
.
In children with acute gastroenteritis attending the emergency department, rhamnose/Swiss grass treatment did not increase stool sIgA concentration compared with placebo
.
Original source
Probiotic stool secretory immunoglobulin A modulation in children with gastroenteritis: a randomized clinical trial.
The American Journal of Clinical Nutrition, Volume 113, Issue 4, April 2021, Pages 905–914, https://doi.
org/10.
1093/ajcn/nqaa369
org/10.
1093/ajcn/nqaa369
Leave a message here